Mark Sabag - 05 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, International Markets Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol: TEVA
Transactions as of: 05 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Mar 2026, 16:23:23 UTC
Previous filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sabag Mark	Executive Vice President, International Markets Commercial	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	09 Mar 2026	0001721442

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+15,723	+5.8%		287,042	05 Mar 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise		-15,723	-25%	$0.000000^*	47,170	05 Mar 2026	Ordinary Shares	15,723		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

Remarks:

Executive Vice President, International Markets Commercial